Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

RXR-alpha variant-targeting agent NM6603

An orally bioavailable small molecule agent that targets retinoid X receptor alpha (RXR-alpha; RXRA) variant, with potential antineoplastic activity. Upon oral administration, RXR-alpha variant-targeting agent NM6603 selectively targets and binds to RXR-alpha variants and inhibits transforming growth factor-beta (TGFb)-mediated signaling pathway. This abrogates TGF-beta-mediated immunosuppression in the tumor microenvironment (TME), increases cytotoxic T-lymphocyte (CTL) activities, and inhibits tumor cell proliferation in susceptible tumor cells. RXR-alpha, a transcription factor that plays an important role in the regulation of the expression of multiple genes, is often modified in various types of tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:retinoid X receptor alpha variant-targeting agent NM6603
RXRA variant-targeting agent NM6603
Code name:NM 6603
NM-6603
NM6603
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search